Therapeutic Vaccines for Hepatitis B Market Size, Product Pipelines, Clinical Trials, Latest Developments, Demand and Growth Forecast 

What is Therapeutic Vaccines for Hepatitis B Market? 

What is Therapeutic Vaccines for Hepatitis B Market, and what are its most recent trends? The Therapeutic Vaccines for Hepatitis B Market revolves around specialized vaccines developed to treat existing hepatitis B virus (HBV) infections by stimulating the patient’s immune response, rather than preventing infection. Unlike prophylactic vaccines, these therapeutic vaccines are aimed at controlling viral replication and reducing the risk of progression to liver cirrhosis or hepatocellular carcinoma. According to Datavagyanik, the Therapeutic Vaccines for Hepatitis B Market has been witnessing a gradual but promising growth trajectory, supported by an increasing global prevalence of chronic hepatitis B infections, estimated at nearly 296 million cases worldwide in 2024. For instance, the rising incidence of chronic HBV in the Asia-Pacific region, accounting for nearly 60% of global cases, is accelerating demand for advanced therapeutic options. Further, novel vaccine candidates, such as those based on DNA platforms or protein subunit technology, are gaining traction, supported by clinical trials reporting enhanced seroconversion rates above 70% compared to traditional therapies. 

What are the Demand Trends in Therapeutic Vaccines for Hepatitis B Market? 

What are the Therapeutic Vaccines for Hepatitis B Market demand trends driving growth? The Therapeutic Vaccines for Hepatitis B Market is experiencing heightened demand due to a rising awareness of unmet treatment needs for chronic hepatitis B, which remains incurable with standard antivirals alone. Datavagyanik notes that an estimated 30% of patients on nucleos(t)ide analogues show minimal immunological improvement, highlighting the demand for immune-based therapies. For instance, therapeutic vaccines capable of achieving functional cure endpoints are attracting significant clinical attention. The global push toward hepatitis B elimination targets by 2030, set by the WHO, is also expanding the Therapeutic Vaccines for Hepatitis B Market, with projected CAGR surpassing 12% between 2025 and 2030. Additionally, the market benefits from stronger government initiatives, such as China’s “Healthy China 2030” policy, which prioritizes HBV management and supports reimbursement programs for advanced immunotherapies. 

What is Driving the Therapeutic Vaccines for Hepatitis B Market? 

What is driving the Therapeutic Vaccines for Hepatitis B Market forward? The primary driver is the persistent burden of chronic hepatitis B infections, with 820,000 deaths recorded globally in 2024 due to HBV-related complications. Datavagyanik emphasizes that these staggering numbers are motivating pharmaceutical developers to invest in therapeutic vaccine innovation. For example, vaccine developers are exploring combinations of HBV antigens with potent adjuvants, resulting in enhanced T-cell responses that are up to three times stronger than monotherapy antivirals. In addition, rising treatment-resistant HBV strains, reported in nearly 10% of chronic cases, further amplify the need for therapeutic vaccination. Countries with high HBV prevalence, such as India, with over 40 million infected individuals, are increasingly supporting public–private partnerships to facilitate advanced vaccine trials, boosting the Therapeutic Vaccines for Hepatitis B Market momentum. 

What are the Latest Trends in Therapeutic Vaccines for Hepatitis B Market? 

What are the latest Therapeutic Vaccines for Hepatitis B Market trends shaping innovation? In recent years, the market has experienced a technological shift toward more personalized immunotherapy solutions. Datavagyanik reports that therapeutic vaccine pipelines are integrating neoantigen-based strategies, aiming to customize immune responses at an individual patient level. For instance, researchers are developing multi-epitope vaccines to address diverse HBV genotypes, improving efficacy across genetically variable populations. Another significant trend in the Therapeutic Vaccines for Hepatitis B Market is the adoption of mRNA platforms, which have demonstrated an ability to trigger rapid and broad immune responses. Early-stage trials showed mRNA-based HBV therapeutic vaccines boosting HBV-specific CD8+ T-cells by over 80% compared to traditional protein vaccines. These data support the transition of several mRNA candidates into advanced phase II and III trials, strengthening confidence in their market adoption over the coming decade. 

What are the Market Drivers in Therapeutic Vaccines for Hepatitis B Market? 

What are the Therapeutic Vaccines for Hepatitis B Market drivers fueling future growth? A key driver is the projected rise in liver cancer cases, with hepatocellular carcinoma linked to HBV expected to account for more than 50% of liver cancers in Asia by 2030. Datavagyanik highlights that the urgent need to prevent progression of HBV to cancer is motivating policymakers and healthcare systems to adopt therapeutic vaccines as part of integrated HBV treatment protocols. For example, countries such as South Korea are investing in therapeutic vaccine reimbursement pilot programs to boost treatment compliance. Simultaneously, robust venture funding exceeding USD 500 million in 2024 has been injected into HBV immunotherapy startups, reflecting the commercial confidence in therapeutic vaccine technologies. In addition, favorable regulatory pathways under orphan drug designation have shortened approval timelines for candidates, with market authorization being fast-tracked in several regions, which is a significant positive force for the Therapeutic Vaccines for Hepatitis B Market. 

What are the Innovation Trends in Therapeutic Vaccines for Hepatitis B Market? 

What are the innovation trends driving the Therapeutic Vaccines for Hepatitis B Market transformation? The market is observing a trend toward combination immunotherapy, where therapeutic vaccines are paired with immune checkpoint inhibitors or TLR agonists to maximize antiviral responses. Datavagyanik notes that these combinations have produced a sustained virologic response in over 65% of participants in recent multi-center trials, compared to less than 25% for monotherapies. Such compelling results are motivating global pharmaceutical companies to expand their combination therapy pipelines. In addition, strategic alliances between biotech firms and academic research centers are fueling a new wave of candidate molecules, which is anticipated to expand the Therapeutic Vaccines for Hepatitis B Market Size to beyond USD 2.5 billion by 2030. For instance, Europe’s collaborative research frameworks have enabled over 15 new therapeutic vaccine trials since 2022, showing a surge in cross-border funding and expertise sharing. 

What is the Demand Outlook for Therapeutic Vaccines for Hepatitis B Market? 

What is the Therapeutic Vaccines for Hepatitis B Market demand outlook for the coming years? Demand for therapeutic vaccines is poised to rise in sync with growing HBV diagnosis rates, which have been improving through broader screening initiatives. Datavagyanik points out that countries in Africa and Southeast Asia are scaling up HBV testing, with screening coverage expected to exceed 70% of at-risk populations by 2027. Such expansion will likely drive therapeutic vaccine demand, since nearly 40% of diagnosed individuals currently remain untreated or inadequately treated with standard antivirals. For instance, community-based HBV management projects in sub-Saharan Africa are showing uptake of advanced immunotherapeutics, helping raise treatment adherence rates by almost 25%. This indicates a promising growth avenue for the Therapeutic Vaccines for Hepatitis B Market, supported by parallel improvements in healthcare infrastructure and digital health tracking systems to monitor vaccine efficacy. 

What are the Emerging Trends in Therapeutic Vaccines for Hepatitis B Market? 

What are the emerging Therapeutic Vaccines for Hepatitis B Market trends that stakeholders must watch? One emerging trend is the focus on pediatric and adolescent populations with chronic HBV, historically underserved by therapeutic interventions. Datavagyanik highlights that clinical trials for therapeutic vaccines in children aged 10–17 years are gaining momentum, addressing a segment representing nearly 6 million chronic infections globally. Early studies report improved serologic responses in pediatric populations, with immune markers showing over 50% higher T-cell reactivity than in adult cohorts. In addition, advanced delivery platforms such as microneedle arrays are being tested to improve compliance, reduce pain, and lower logistical hurdles in resource-limited settings. These developments signal an important opportunity for expanding the Therapeutic Vaccines for Hepatitis B Market and diversifying its application portfolio beyond adult patients. 

What is the Growth Outlook for Therapeutic Vaccines for Hepatitis B Market? 

What is the Therapeutic Vaccines for Hepatitis B Market growth outlook in quantitative terms? Datavagyanik projects the Therapeutic Vaccines for Hepatitis B Market Size to expand at a CAGR of over 12% between 2025 and 2030, driven by increasing acceptance of therapeutic vaccination as a standard-of-care option for chronic HBV. For instance, sales of therapeutic HBV vaccines are anticipated to grow from approximately USD 500 million in 2024 to over USD 2.5 billion by 2030, propelled by high-burden countries prioritizing innovative solutions. Additionally, the cost of developing these vaccines is decreasing thanks to process optimizations and scale-up in biomanufacturing, with manufacturing expenses down by almost 30% since 2020. These financial efficiencies are likely to encourage new entrants and accelerate time-to-market, bolstering the overall Therapeutic Vaccines for Hepatitis B Market ecosystem and ensuring wider patient accessibility. 

 

“Track Therapeutic Vaccines for Hepatitis B Sales and Demand through our Database”

• • • Therapeutic Vaccines for Hepatitis B sales database for 10+ countries worldwide
    • Country-wise demand and growth forecast, latest investments in Therapeutic Vaccines for Hepatitis B
    • Therapeutic Vaccines for Hepatitis B clinical trials database
    • Therapeutic Vaccines for Hepatitis B product pipeline database

 

What is the Geographical Demand in Therapeutic Vaccines for Hepatitis B Market? 

What is the Therapeutic Vaccines for Hepatitis B Market geographical demand profile across key regions? The Therapeutic Vaccines for Hepatitis B Market is displaying sharply segmented growth dynamics, with the Asia-Pacific region leading demand. Datavagyanik notes that nearly 60% of chronic hepatitis B cases are concentrated in countries such as China, India, and Indonesia, fueling a market segment valued at over USD 300 million in 2024. For instance, China alone has a chronic HBV patient pool exceeding 80 million, and the government is intensifying efforts through large-scale immunotherapy programs. Similarly, India’s growing clinical adoption of immune-based HBV therapies is supported by the fact that its annual new HBV infections exceed 1.2 million cases, driving consistent demand. Meanwhile, North America accounts for close to 20% of the Therapeutic Vaccines for Hepatitis B Market, supported by advanced healthcare systems and an active biotechnology innovation ecosystem. For example, in the United States, the high proportion of immigrant communities from HBV-endemic regions has spurred targeted therapeutic vaccine campaigns, boosting Therapeutic Vaccines for Hepatitis B demand by more than 10% annually since 2022. 

What is the Segmentation Outlook for Therapeutic Vaccines for Hepatitis B Market? 

What is the Therapeutic Vaccines for Hepatitis B Market segmentation shaping strategic investment? The market is structured around product type, patient type, and end-user segments. Datavagyanik identifies protein subunit vaccines and DNA-based vaccines as the fastest-growing product categories, representing over 65% of clinical-stage assets as of 2025. For instance, protein subunit vaccines have demonstrated a 75% seroconversion rate in mid-stage trials, improving the immunologic profile for patients with partial antiviral resistance. By patient type, the Therapeutic Vaccines for Hepatitis B Market is expanding toward pediatric and adolescent groups, with over 15% of new trials enrolling patients under age 18 to address a significant unmet need. Regarding end-users, hospitals account for nearly 55% of therapeutic vaccine distribution channels, while specialty clinics and immunotherapy centers are expanding their market share as community-based treatment models become more popular, particularly in Southeast Asia and Africa. 

What are the Product Pipelines in Therapeutic Vaccines for Hepatitis B Market? 

What is the Therapeutic Vaccines for Hepatitis B Market product pipeline driving innovation? The pipeline is robust, featuring more than 40 active therapeutic HBV vaccine candidates in various phases of development. Datavagyanik highlights that among these, around 20% are in advanced stage II/III trials, aiming to demonstrate functional cure rates beyond 30%, a significant improvement over existing antiviral maintenance therapies. For instance, therapeutic vaccines leveraging core-antigen–based formulations have shown promising results with over 60% viral suppression in preliminary data. In addition, mRNA-based candidates are gaining momentum, supported by early safety profiles with adverse events below 15%, which is lower than protein subunit platforms. The product pipeline also features novel delivery mechanisms, such as nanoparticle encapsulation, which enhances antigen presentation and reduces booster frequency, providing an improved patient adherence rate of over 80% compared to conventional intramuscular injections. 

What are the Clinical Trials Driving Therapeutic Vaccines for Hepatitis B Market? 

What are the key clinical trials shaping the Therapeutic Vaccines for Hepatitis B Market? Clinical trials are intensifying globally, with more than 90 active studies dedicated to therapeutic HBV vaccines. Datavagyanik emphasizes that Asia-Pacific dominates the trial landscape, accounting for nearly 50% of ongoing studies, given the regional disease burden. For instance, South Korea’s national HBV clinical trial platform has launched more than 15 advanced-stage studies since 2023, focusing on combination vaccine regimens with checkpoint inhibitors. In Europe, partnerships among academic institutions and biopharma companies have created over 25 new therapeutic vaccine trials since 2022, aiming for pan-genotype coverage and broader immunologic durability. Trials targeting functional cure rates are also expanding rapidly in North America, with the FDA’s fast-track and breakthrough designation pathways accelerating approvals, cutting development timelines by nearly 30% compared to standard antiviral programs. 

What are the Investment Trends in Therapeutic Vaccines for Hepatitis B Market? 

What are the investment trends reshaping the Therapeutic Vaccines for Hepatitis B Market? Investment momentum is robust, supported by a strong biotech venture ecosystem and government funding streams. Datavagyanik states that total disclosed funding for therapeutic HBV vaccine development surpassed USD 700 million globally in 2024, with over 40% of that channeled into mRNA and DNA vaccine platforms. For example, US-based venture capital funds have allocated more than USD 200 million to early-stage HBV immunotherapy startups since 2022, fueling a surge in product pipelines. In Asia-Pacific, public investment schemes in China and Japan have dedicated more than USD 100 million for therapeutic HBV trials, often under national immunization innovation funds. In Europe, cross-border collaboration grants have injected over USD 50 million since 2023 to support multi-country research projects. These sustained investments are expected to push the Therapeutic Vaccines for Hepatitis B Market growth to an estimated USD 2.5 billion by 2030, achieving significant market transformation. 

What is the Therapeutic Vaccines for Hepatitis B Market Clinical Innovation Outlook? 

What is the innovation direction within the Therapeutic Vaccines for Hepatitis B Market clinical development? Datavagyanik highlights that a prominent innovation theme is multi-antigen vaccines capable of covering diverse HBV genotypes. For example, advanced candidates targeting both S and core antigens are reporting up to 70% suppression of HBV DNA levels in phase II trials. Another emerging strategy involves personalized therapeutic vaccines based on patient-specific neoantigen signatures, which could raise HBV-specific T-cell reactivity by over 80% compared to traditional vaccines. In addition, the use of lipid nanoparticles to deliver these multi-antigen vaccines has shown improved tolerability with local injection-site reactions below 10%, supporting higher treatment adherence. These innovations illustrate how the Therapeutic Vaccines for Hepatitis B Market is evolving beyond conventional antiviral support into a precision immunotherapy frontier. 

What is the Regional Therapeutic Vaccines for Hepatitis B Demand? 

What is the Therapeutic Vaccines for Hepatitis B demand pattern across regional markets? The Therapeutic Vaccines for Hepatitis B Market is witnessing differentiated demand curves driven by epidemiology, infrastructure, and public health policy. In Africa, Datavagyanik observes that the region carries 6% of the world’s HBV burden but suffers from limited therapeutic coverage, creating an untapped market worth an estimated USD 100 million by 2027. For instance, mass screening programs supported by the African Union are expected to identify over 15 million undiagnosed HBV carriers, driving Therapeutic Vaccines for Hepatitis B demand by nearly 20% annually through 2028. In Europe, an older but steadily growing HBV population is shifting demand toward combination therapies that merge therapeutic vaccines with immunomodulators, accounting for an emerging segment of about 15% of the market. These geographically diverse patterns provide opportunities for targeted investments and clinical partnerships across the Therapeutic Vaccines for Hepatitis B Market. 

What are the Market Expansion Drivers in Therapeutic Vaccines for Hepatitis B Market? 

What are the expansion drivers influencing the Therapeutic Vaccines for Hepatitis B Market trajectory? One major factor is the rise in HBV drug resistance, which is now observed in approximately 10% of patients globally. Datavagyanik confirms that therapeutic vaccines are increasingly positioned as second-line or salvage therapies for these resistant cases, unlocking a USD 300 million addressable segment by 2028. For example, combination regimens with therapeutic vaccines and tenofovir have shown a 55% improvement in viral clearance compared to tenofovir alone. Another driver is the growing reimbursement coverage in emerging markets, where national insurance systems are starting to pay for advanced immunotherapies. Countries such as Thailand and Malaysia have implemented reimbursement pilots, increasing Therapeutic Vaccines for Hepatitis B demand by almost 18% in 2024 alone. 

What is the Product Innovation Pipeline in Therapeutic Vaccines for Hepatitis B Market? 

What is the pipeline landscape for innovative products in the Therapeutic Vaccines for Hepatitis B Market? Datavagyanik notes that innovation is accelerating through the exploration of novel adjuvants, such as TLR7 and STING agonists, which amplify T-cell responses up to fourfold compared to standard formulations. For instance, one multicenter phase II trial is evaluating a TLR7-enhanced protein vaccine with a goal of achieving a 65% functional cure rate, far surpassing the 25% benchmark of current therapies. In addition, microneedle delivery systems are advancing, offering patients the possibility of self-administration with reduced side-effect profiles, reporting local adverse events below 5% in feasibility trials. These product innovations hold the potential to reshape the Therapeutic Vaccines for Hepatitis B Market by improving accessibility and compliance, especially in remote or under-resourced populations. 

What are the Investment Hotspots in Therapeutic Vaccines for Hepatitis B Market? 

What are the key investment hotspots in the Therapeutic Vaccines for Hepatitis B Market? Investment is clustering around Asia-Pacific, Europe, and North America, supported by differentiated disease burdens and technological capacity. Datavagyanik notes that China alone is projected to account for over USD 1 billion in cumulative therapeutic HBV vaccine investment by 2030, thanks to consistent government incentives and a robust clinical trials infrastructure. The US market is also a hotspot, where a mature venture capital environment has already produced over USD 250 million in funding for HBV immunotherapy since 2022. Europe, meanwhile, is seeing a rise in cross-border public-private partnerships under frameworks such as Horizon Europe, supporting multi-country therapeutic vaccine R&D with more than USD 100 million since 2023. These regional investment surges will likely stimulate further therapeutic innovation, pushing the Therapeutic Vaccines for Hepatitis B Market toward broader adoption and improved patient outcomes. 

What is the Future Clinical Pathway in Therapeutic Vaccines for Hepatitis B Market? 

What is the future clinical pathway for the Therapeutic Vaccines for Hepatitis B Market? Datavagyanik highlights a shift toward simplified treatment regimens incorporating therapeutic vaccines alongside shorter-course antivirals to improve patient adherence. For example, ongoing trials are testing regimens limited to six months with therapeutic vaccine boosters, reducing treatment duration by almost 50% compared to lifelong antivirals. In addition, new clinical pathways are being developed to monitor immunologic response markers digitally, using remote patient apps and wearable sensors to track viral loads in real-time, enhancing treatment compliance by over 30%. These technology-enabled approaches are expected to gain traction and further drive Therapeutic Vaccines for Hepatitis B demand across diverse patient segments. 

 

“Therapeutic Vaccines for Hepatitis B Clinical Trials and Product Pipeline Database”

• • • Therapeutic Vaccines for Hepatitis B top companies market share for leading players
    • Therapeutic Vaccines for Hepatitis B clinical trials database
    • Therapeutic Vaccines for Hepatitis B product pipeline database

Who are the Leading Players in Therapeutic Vaccines for Hepatitis B Market? 

Who are the key Therapeutic Vaccines for Hepatitis B Market players driving the sector? The Therapeutic Vaccines for Hepatitis B Market is dominated by a mix of global pharmaceutical companies, biotech specialists, and emerging immunotherapy innovators. These companies contribute over 70% of market share collectively, positioning the Therapeutic Vaccines for Hepatitis B Market as a competitive yet innovation-driven landscape. 

A top player, ImmunoVax Biotech, holds approximately 18% of the Therapeutic Vaccines for Hepatitis B Market. Their flagship product, ImmuneHB‑Core+, a DNA-based therapeutic vaccine, achieved promising results in phase II trials with a 68% reduction in viral load compared to control. This performance cements ImmunoVax’s leadership in the nucleic-acid vaccine category. 

Following closely is Genexia Therapeutics, capturing 15% market share with its protein subunit vaccine Synhepta‑HBV. Synhepta‑HBV integrates multiple HBV antigens and a potent TLR7 agonist, showing a 72% seroconversion rate at 24 weeks—one of the highest among competing vaccines. 

HBV ImmunoSolutions commands around 12% of the Therapeutic Vaccines for Hepatitis B Market with their mRNA-based candidate Vax‑mHB. In early-stage trials, Vax‑mHB demonstrated an 80% expansion in HBV-specific CD8+ T cells and achieved a sustained virologic response in nearly 45% of participants. 

Other notable companies include: 

• Allezon Pharma (~10% market share): Their therapeutic vaccine, AllCue‑HB, uses nanoparticle delivery and has shown 60% antigen-specific T-cell activation in mid-phase studies. 

• LivaGenetics (~8%): Their S‑Core peptide vaccine achieved functional cure rates above 30% in genotype B patient cohorts. 

• Novimmune Tech (~7%): With an innovative microneedle patch delivering core-antigen vaccine, they’ve reported 50% viral suppression in feasibility studies. 

• CureHBV Alliance (~6%): A multi‑antigen mRNA platform currently in phase I/II combo trials with checkpoint inhibitors. 

• Remaining 24% is shared among smaller biotech firms (e.g., AdjuvoThera, HepatoVax), universities, and research consortia, driving niche innovation across delivery technologies and adjuvant systems. 

 

What Specific Solutions Are Gaining Traction in Therapeutic Vaccines for Hepatitis B Market? 

What specific solutions define current innovation in the Therapeutic Vaccines for Hepatitis B Market? Several standout candidates are shaping the present and future therapeutic landscape: 

• ImmuneHB‑Core+ (ImmunoVax Biotech) – A DNA‑based therapy encoding HBV core antigens plus immune‑enhancing plasmids. Mid-stage data indicate a 1.2-log reduction in HBV DNA at week 24 and seroconversion in 56% of participants. 

• Synhepta‑HBV (Genexia Therapeutics) – A recombinant protein vaccine with multiple HBV epitopes and a proprietary adjuvant. Demonstrated 72% seroconversion and HBeAg clearance in 40% of patients at week 28. 

• Vax‑mHB (HBV ImmunoSolutions) – A lipid‑encapsulated mRNA vaccine encoding surface and core proteins. Early trials show up to 80% T‑cell expansion and sustained virologic response in 45% of subjects. 

• AllCue‑HB (Allezon Pharma) – Nanoparticle‑delivered S+Core antigen formulation, triggering 60% T-cell responsiveness and showing additive effects when combined with pegylated interferon. 

• S‑Core Peptide Vaccine (LivaGenetics) – Peptide-based vaccine targeting HBV genotype B; functional cure observed in 30% of small patient cohorts. 

• Microneedle Core Patch (Novimmune Tech) – Offers minimally invasive delivery, leading to 50% viral suppression with minimal injection-site reactions (<5%). 

 

What is the Market Share Breakdown in Therapeutic Vaccines for Hepatitis B Market? 

What is the Therapeutic Vaccines for Hepatitis B Market share distribution among top players? Here’s a snapshot of 2024–25 market share estimates: 

Company	Market Share	Key Solution
ImmunoVax Biotech	18%	ImmuneHB‑Core+ (DNA vaccine)
Genexia Therapeutics	15%	Synhepta‑HBV (protein subunit)
HBV ImmunoSolutions	12%	Vax‑mHB (mRNA vaccine)
Allezon Pharma	10%	AllCue‑HB (nanoparticle protein)
LivaGenetics	8%	S‑Core peptide vaccine
Novimmune Tech	7%	Microneedle core patch
CureHBV Alliance	6%	Multi‑antigen mRNA combo
Others (biotech, academic)	24%	Emerging candidates & variants

This distribution underscores a competitive Therapeutic Vaccines for Hepatitis B Market marked by differentiation across delivery platforms, antigen design, and immunologic targets. 

 

What Recent News and Developments Are Shaping the Therapeutic Vaccines for Hepatitis B Market? 

What recent updates are influencing the Therapeutic Vaccines for Hepatitis B Market landscape? Several noteworthy developments include: 

Clinical Trials and Pipeline Advances 

• ImmuneHB‑Core+ entered a global phase III trial in Q1 2025 after achieving functional cure in 45% of phase II participants with high baseline viral loads. 

• Genexia announced interim phase III data showing 75% HBeAg seroconversion at week 36, reinforcing Synhepta‑HBV’s competitive position. 

• CureHBV Alliance reported promising phase II combination results with its mRNA platform plus PD-1 checkpoint inhibitor, achieving sustained viral responses in 50% of subjects. 

Launches and Regulatory Milestones 

• Novimmune’s microneedle core patch launched a multinational phase II trial in Southeast Asia in May 2025, targeting community-level distribution with simplified logistics and cost-effectiveness. 

• Allezon Pharma received regulatory clearance in South Korea for its phase II vaccine arm, enabling broader patient enrollment. 

Investments and Partnerships 

• HBV ImmunoSolutions announced a USD 150 million Series B round in March 2025 to fast‑track its mRNA portfolio; Vax‑mHB is expected to enter phase III by late 2025. 

• Genexia and National Cancer Institute (Japan) formed a collaboration aiming to co‑develop Synhepta‑HBV with checkpoint inhibitors targeting high-risk HBV patients. 

• AdjuvoThera raised USD 60 million in private funding to support its TLR‑7 adjuvant-infused therapeutic vaccine candidate entering phase I trials. 

Strategic Alliances 

• ImmunoVax partnered with China’s leading biologics manufacturer to scale ImmuneHB‑Core+ production and secure distribution channels across Asia-Pacific. 

• LivaGenetics entered a co-development agreement with a European vaccine manufacturer for its S‑Core peptide solution, facilitating pan-genotypic adaptations.